VESALIUS-CV
2026
Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke
In 12,257 patients at high cardiovascular risk without prior myocardial infarction or stroke, evolocumab reduced major adverse cardiovascular events compared with placebo.
Result
Efficacy: Two primary endpoints: coronary death, myocardial infarction or ischemic stroke (3-point MACE), and the same composite plus ischemia-driven arterial revascularization (4-point MACE).HR 0.75 (95% CI 0.65-0.86)
Below 1 favours evolocumab, above 1 favours placebo.
- Absolute difference
- 1.8 points
- NNT
- 56
Absolute difference and NNT are derived from the event rates.
Also reported: 4-point MACE 13.4% vs 16.2% (HR 0.81; 95% CI 0.73-0.89); median LDL-C at week 48 45 mg/dL vs 109 mg/dL; no new safety signals.
- Design
- Randomized, double-blind, placebo-controlled trial; evolocumab 140 mg subcutaneously every 2 weeks vs placebo added to background lipid-lowering therapy in patients with atherosclerosis or high-risk diabetes and LDL-C ≥ 90 mg/dL but no prior myocardial infarction or stroke; median follow-up 4.6 years; median age 66 years, 43% women, 93% White.
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117-127.doi 10.1056/nejmoa2514428